Molecular diagnostics for hereditary cancer, oncology, and pharmacogenomics
Myriad Genetics runs a molecular testing business whose stack pairs lab instrumentation (Illumina, Tecan) with clinical interoperability (Epic, HL7, FHIR) and a Snowflake + dbt + Looker analytics layer, under HITRUST and ISO 27001 controls. Accelerating hiring is heavily sales-led, and job posts center on a commercial problem: driving physician adoption of pharmacogenomic, oncology, and MRD tests rather than building new lab capacity.
Myriad Genetics is a public molecular diagnostics and precision medicine company headquartered in Salt Lake City, Utah, founded in 1991. It develops tests that estimate disease risk or progression and inform treatment choices, with focus areas including hereditary cancer, prostate and breast cancer, pharmacogenomics, carrier screening, and companion diagnostics. The company sells to clinicians and health systems across the United States, supported by Salesforce Sales and Service Cloud. It employs between 1,001 and 5,000 people.
Myriad uses Salesforce (Sales Cloud, Service Cloud, Apex), Epic Systems with HL7 and FHIR, Snowflake, dbt, Looker, Python, Django, React, TypeScript, PostgreSQL, Oracle, SQL Server, plus Illumina and Tecan lab systems.
Yes. Sales is the dominant hiring area, with healthcare roles next, and hiring is accelerating. Roles skew senior and are based in the United States, focused on territory plans and test adoption.
Job posts point to integrating MRD testing into its oncology strategy, a structured MRD rollout, clinical messaging for new data, product education, and territory expansion plans.
Other companies in the same industry, closest in size
Myriad Genetics's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.